Background image

The Development of CAD 1883 through Proof-of-Concept in Essential Tremor

Posted on July 25, 2025

Tim Piser, chief scientific officer with Novartis (formerly Cadent Therapeutics), talks about the company’s development of the CAD-1883 for the treatment of essential tremor. One study has already been completed and now Cadent is positioned for further development of this medication.